CYBQY: AI 评分 59/100 — AI 分析 (4月 2026)

CYBERDYNE Inc. is a Japanese company specializing in the research, development, and production of robotic technologies, including the Hybrid Assistive Limb (HAL). HAL is used in medical, welfare, and industrial applications to enhance and support physical capabilities.

Key Facts: AI Score: 59/100 Sector: Healthcare

公司概况

概要：

CYBERDYNE Inc., based in Japan, develops and produces robotic technologies like the Hybrid Assistive Limb (HAL) for medical, welfare, and industrial sectors. With a focus on enhancing physical capabilities, the company operates in a competitive landscape, balancing innovation with financial sustainability, reflected in its negative profit margin.

CYBQY是做什么的？

CYBERDYNE Inc., founded in 2004 and headquartered in Tsukuba, Japan, is a pioneering robotics company focused on enhancing human capabilities through its innovative Hybrid Assistive Limb (HAL) technology. HAL is designed to assist and rehabilitate individuals with mobility impairments, as well as enhance the physical performance of workers in industrial settings. The company's product portfolio includes HAL for medical use (lower limb and single joint types), non-medical HAL (lower limb, single joint, and lumbar types), HAL peripherals, cleaning robots, and transportation robots for indoor environments. Additionally, CYBERDYNE offers Acoustic X, a high-speed light pulse LED array light source for real-time photoacoustic imaging. CYBERDYNE's services extend to Cybernics Treatment, utilizing HAL to improve function in patients with spinal cord injury, stroke, and neuromuscular diseases. They also provide HAL FIT for brain-nerve-musculoskeletal system enhancement, MTX Neuro HAL Plus for athletes' brain-nerve function enhancement, and Neuro HALFIT for physical function enhancement. Beyond medical and welfare applications, CYBERDYNE is involved in providing rescue support in disaster sites, heavy labor support for factories and plants, and even entertainment applications. The company's global reach is facilitated through its ADR (American Depositary Receipt), CYBQY, allowing US investors to participate in its growth. CYBERDYNE faces competition from other medical device and robotics companies, requiring continuous innovation and strategic partnerships to maintain its market position.

CYBQY的投资论点是什么？

CYBERDYNE Inc. presents a unique investment opportunity in the burgeoning field of medical and industrial robotics. The company's core value driver is its HAL technology, which has applications in healthcare, welfare, and industrial sectors. Growth catalysts include the increasing adoption of robotic rehabilitation therapies and the expansion of HAL into new markets and applications, such as disaster relief and heavy industry. Key metrics to watch include revenue growth from HAL sales and service contracts, as well as progress in clinical trials and regulatory approvals for new medical applications. However, investors should be aware of potential risks, including the company's negative profit margin (-0.1%), which indicates a need for improved cost management and revenue generation. The company's small market capitalization ($0.34B) and OTC listing also introduce liquidity and volatility concerns. The company's P/E ratio is -22098.38. The beta is 0.55.

CYBQY在哪个行业运营？

The medical device industry is experiencing rapid growth, driven by technological advancements, an aging population, and increasing demand for innovative healthcare solutions. The robotic rehabilitation market, in particular, is expected to see significant expansion in the coming years. CYBERDYNE operates in this dynamic landscape, competing with established medical device companies and specialized robotics firms. Competitors include BCCOY (Bic Corp), BRSYF (Bristol Myers Squibb), CLLKF (Coloplast A/S), GNFTF (Genfit SA), and JWCTF (JWC Rehabilitation). The company's success will depend on its ability to differentiate its HAL technology, secure regulatory approvals, and establish strategic partnerships.

Medical - Devices

Healthcare

CYBQY有哪些增长机遇？

Expansion of HAL in Rehabilitation Centers: CYBERDYNE has the opportunity to expand the adoption of its HAL technology in rehabilitation centers globally. The increasing prevalence of stroke and spinal cord injuries drives the demand for advanced rehabilitation solutions. By partnering with leading rehabilitation hospitals and clinics, CYBERDYNE can increase its market penetration. The global rehabilitation equipment market is projected to reach $20 billion by 2028, providing a substantial growth opportunity for CYBERDYNE.
Industrial Applications of HAL for Enhanced Productivity: CYBERDYNE can capitalize on the growing demand for exoskeletons in industrial settings to enhance worker productivity and reduce workplace injuries. HAL can be deployed in factories, construction sites, and logistics facilities to assist workers with heavy lifting and repetitive tasks. The industrial exoskeleton market is expected to reach $1.8 billion by 2025, offering a significant growth avenue for CYBERDYNE. Success hinges on demonstrating tangible ROI for industrial clients through increased efficiency and reduced injury rates.
Strategic Partnerships with Healthcare Providers: Forming strategic alliances with healthcare providers and insurance companies can facilitate the adoption of Cybernics Treatment, which utilizes HAL for neurological rehabilitation. These partnerships can streamline the reimbursement process and increase patient access to CYBERDYNE's innovative therapies. The global neurological disease treatment market is projected to reach $15 billion by 2027, creating a substantial market opportunity for CYBERDYNE's Cybernics Treatment.
Development of Next-Generation HAL with AI Integration: CYBERDYNE can enhance the capabilities of its HAL technology by integrating artificial intelligence (AI) and machine learning algorithms. AI-powered HAL can provide personalized assistance and adapt to individual patient needs, improving rehabilitation outcomes. The integration of AI can also enable predictive maintenance and remote monitoring of HAL devices, reducing downtime and improving customer satisfaction. The AI in healthcare market is expected to reach $34 billion by 2025, providing a technological tailwind for CYBERDYNE's innovation efforts.
Geographic Expansion into Emerging Markets: CYBERDYNE has the opportunity to expand its presence in emerging markets, such as China, India, and Southeast Asia, where there is a growing demand for advanced medical and industrial technologies. These markets offer significant growth potential due to their large populations, increasing healthcare spending, and growing industrial sectors. However, CYBERDYNE will need to adapt its products and business models to meet the specific needs and regulatory requirements of each market. Success depends on building strong local partnerships and establishing a robust distribution network.

CYBERDYNE Inc. operates in the innovative field of robotic exoskeletons with its HAL (Hybrid Assistive Limb) technology.
The company's HAL technology has applications in medical rehabilitation, industrial support, and disaster relief.
CYBERDYNE's gross margin stands at 49.9%, indicating a solid foundation for profitability if operational efficiencies improve.
The company has a market capitalization of $0.34 billion, reflecting its current valuation in the market.
CYBERDYNE's shares are traded on the OTC market as an ADR (American Depositary Receipt), ticker symbol CYBQY.

CYBQY提供哪些产品和服务？

Researches and develops robotic technologies, primarily the Hybrid Assistive Limb (HAL).
Produces and sells HAL devices for medical, welfare, and industrial applications.
Leases HAL equipment to various organizations and individuals.
Maintains and services HAL devices to ensure optimal performance.
Offers Cybernics Treatment, a rehabilitation therapy using HAL for neurological conditions.
Provides cleaning and transportation robots for indoor environments.
Develops and markets Acoustic X, a high-speed light pulse LED array light source for photoacoustic imaging.
Offers HAL FIT for brain-nerve-musculoskeletal system enhancement.

CYBQY如何赚钱？

Direct sales of HAL devices to hospitals, rehabilitation centers, and industrial clients.
Leasing of HAL equipment to organizations and individuals.
Service and maintenance contracts for HAL devices.
Revenue from Cybernics Treatment sessions.
Sales of HAL peripherals and accessories.

Hospitals and rehabilitation centers using HAL for patient rehabilitation.
Industrial companies deploying HAL to enhance worker productivity and safety.
Individuals with mobility impairments using HAL for personal assistance.
Research institutions utilizing HAL for scientific studies.
Athletes using MTX Neuro HAL Plus to enhance brain-nerve functions.

Proprietary HAL Technology: CYBERDYNE's HAL technology is protected by patents and trade secrets, creating a barrier to entry for competitors.
First-Mover Advantage: CYBERDYNE was among the first companies to develop and commercialize robotic exoskeletons, giving it a head start in the market.
Clinical Evidence: CYBERDYNE has accumulated clinical evidence supporting the efficacy of HAL in improving rehabilitation outcomes, enhancing its credibility with healthcare providers.
Brand Recognition: CYBERDYNE has established a strong brand reputation in the robotics industry, particularly in Japan.

什么因素可能推动CYBQY股价上涨？

Ongoing: Continued adoption of HAL technology in rehabilitation centers and hospitals.
Ongoing: Expansion of HAL applications in industrial settings for worker support.
Upcoming: Potential regulatory approvals for new medical applications of HAL.
Upcoming: Strategic partnerships with healthcare providers and insurance companies.
Ongoing: Development of next-generation HAL with AI integration.

CYBQY的主要风险是什么？

Ongoing: Negative profit margin indicates financial instability.
Potential: Competition from established medical device companies and specialized robotics firms.
Potential: Regulatory hurdles and reimbursement challenges.
Potential: Technological obsolescence.
Ongoing: Currency risk associated with the ADR structure.

CYBQY的核心优势是什么？

Innovative HAL technology with diverse applications.
Strong brand recognition in the robotics industry.
Established partnerships with research institutions and healthcare providers.
First-mover advantage in the robotic exoskeleton market.

CYBQY的劣势是什么？

Negative profit margin indicates financial challenges.
Small market capitalization and OTC listing raise liquidity concerns.
Limited geographic presence outside of Japan.
Reliance on a single core technology (HAL).

CYBQY有哪些机遇？

Expansion into new markets and applications, such as disaster relief and heavy industry.
Strategic partnerships with healthcare providers and insurance companies.
Development of next-generation HAL with AI integration.
Increasing adoption of robotic rehabilitation therapies.

CYBQY面临哪些威胁？

Competition from established medical device companies and specialized robotics firms.
Regulatory hurdles and reimbursement challenges.
Technological obsolescence.
Economic downturns affecting healthcare spending.

CYBQY的竞争对手是谁？

Bic Corp — Focuses on consumer products rather than medical devices. — (BCCOY)
Bristol Myers Squibb — Pharmaceutical company with a different focus than robotic rehabilitation. — (BRSYF)
Coloplast A/S — Focuses on ostomy, continence, wound, and skin care, not robotic exoskeletons. — (CLLKF)
Genfit SA — Biopharmaceutical company focused on metabolic and liver diseases. — (GNFTF)
JWC Rehabilitation — Provides rehabilitation services and products, potentially overlapping with CYBERDYNE's HAL applications. — (JWCTF)

Key Metrics

MoonshotScore: 59/100

Company Profile

CEO: Yoshiyuki Sankai
Headquarters: Tsukuba, JP
Employees: 227
Founded: 2021

AI Insight

AI analysis pending for CYBQY

ADR Level: 1
ADR Ratio: 1:1
Home Market Ticker: CYBQ

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does CYBERDYNE Inc. do?

CYBERDYNE Inc. is a Japanese robotics company specializing in the development, production, and distribution of the Hybrid Assistive Limb (HAL). HAL is a wearable robotic device designed to assist and enhance the physical capabilities of its users. The company operates in the medical, welfare, and industrial sectors, providing solutions for rehabilitation, mobility assistance, and workplace productivity. CYBERDYNE's business model revolves around the sale, lease, and maintenance of HAL devices, as well as the provision of Cybernics Treatment, a rehabilitation therapy utilizing HAL for neurological conditions.

What do analysts say about CYBQY stock?

As of March 16, 2026, formal analyst ratings for CYBQY are limited due to its OTC market listing and smaller market capitalization. Investors should conduct their own due diligence and consider the company's financial performance, growth prospects, and risk factors before making any investment decisions. Key valuation metrics include the company's price-to-earnings ratio (-22098.38), gross margin (49.9%), and market capitalization ($0.34 billion). Growth considerations include the potential for HAL to expand into new markets and applications, as well as the company's ability to improve its profitability.

What are the main risks for CYBQY?

CYBERDYNE Inc. faces several risks, including its negative profit margin, which indicates financial instability. The company also faces competition from established medical device companies and specialized robotics firms. Regulatory hurdles and reimbursement challenges could hinder the adoption of HAL in healthcare settings. Technological obsolescence is another risk, as advancements in robotics and artificial intelligence could render HAL less competitive. Finally, currency risk associated with the ADR structure could impact the value of CYBQY for U.S. investors.